Latest kidney cancer news
Stereotactic radiotherapy for metastatic kidney cancer patients on TKIs
This phase 2 study looked at the use of stereotactic [...]
ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of non-clear cell kidney cancer
Non-clear cell RCC is about 20-25% of all RCC diagnoses [...]
ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of kidney cancer
KEYNOTE-427 is an open-label, single-arm, phase II study to look [...]
ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up
The use of two medicines together (combination therapies) for previously [...]
55,000 cancer patients miss treatment target over 6 years
Cancer Research UK has reported that over the past 6 [...]
ESMO 2021: Pembrolizumab as adjuvant therapy
Adjuvant therapy is medication that is given in addition to [...]
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo kidney cancer sunitinib cabozantinib Sutent progression-free survival NHS England biomarkers ipilimumab pembrolizumab Cabometyx axitinib COVID-19 cancer survival non-clear cell kidney cancer VEGF inhibitors Inlyta coronavirus risk factors Yervoy adjuvant therapy Keytruda targeted therapy metastases papillary RCC everolimus biological markers ASCO Afinitor cancer outcomes first-line treatment NICEArchives
- 2025: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2024: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
